Venture Fund Vii, L.P.Arch ... Net Worth

The estimated Net Worth of Venture Fund Vii, L.P.Arch ... is at least $20 million dollars as of 22 December 2020. Venture Arch owns over 300,000 units of 908 Devices stock worth over $19,980,407 and over the last 4 years Venture sold MASS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Arch MASS stock SEC Form 4 insiders trading

Venture has made over 1 trades of the 908 Devices stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture bought 300,000 units of MASS stock worth $6,000,000 on 22 December 2020.

The largest trade Venture's ever made was buying 300,000 units of 908 Devices stock on 22 December 2020 worth over $6,000,000. On average, Venture trades about 300,000 units every 0 days since 2020. As of 22 December 2020 Venture still owns at least 5,725,045 units of 908 Devices stock.

You can see the complete history of Venture Arch stock trades at the bottom of the page.

Insiders trading at 908 Devices

Over the last 4 years, insiders at 908 Devices have traded over $16,182,689 worth of 908 Devices stock and bought 826,585 units worth $15,798,345 . The most active insiders traders include Keith Crandell, Kevin J. Knopp et E Kevin Hrusovsky. On average, 908 Devices executives and independent directors trade stock every 10 days with the average trade being worth of $64,663. The most recent stock trade was executed by Christopher D. Brown on 7 August 2024, trading 6,328 units of MASS stock currently worth $9,998.

What does 908 Devices do?

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Complete history of Venture Arch stock trades at 908 Devices

908 Devices executives and stock owners

908 Devices executives and other stock owners filed with the SEC include:

• Dr. Kevin J. Knopp Ph.D.,
  Co-Founder, CEO, Pres & Director
• Michael S. Turner Esq., J.D.,
  VP, Sec. & Gen. Counsel
• Dr. Trent A. Basarsky Ph.D.,
  VP of Corp. Devel.
• Maura Fitzpatrick,
  VP of Product Management & Marketing
• Joseph H. Griffith IV,
  CFO & Treasurer
• Dr. Scott Miller Ph.D.,
  Co-founder & Director of MS Engineering
• Michael Jobin,
  Co-Founder & Director of Product Devel.
• Andrew Bartfay,
  Co-Founder & Director of Hardware Devel.
• Steve Araiza,
  Co-founder & Software Architect
• Dr. Christopher David Brown Ph.D.,
  Co-Founder, CTO, VP of R&D and Member of Scientific Advisory Board
• Michael S. Turner,
  Chief Legal & Admin Officer
• John Kenneweg,
  Vice President, Government
• Kevin J. Knopp,
  President and CEO
• Sharon Kedar,
  Director
• Venture Fund Vii, L.P.Arch ...,
  
• John Michael Ramsey,
  Director
• Jeffrey P. George,
  
• Fenel M Eloi,
  
• Christopher D. Brown,
  Chief Product Officer
• Trent A. Basarsky,
  VP, Corporate Development
• Joseph H. Iv Griffith,
  Chief Financial Officer
• Nicolas Barthelemy,
  
• Marcia Eisenberg,
  
• Anthony Hunt,
  
• Keith Crandell,
  
• E Kevin Hrusovsky,
  
• Mark Spoto,
  
• Michele M. Leonhart,
  
• Maura Fitzpatrick,
  VP, Product Management & Mktg